Nav 1.7 Prion Undisclosed C9orf72 Huntington NEUROPATHIC PAIN PRION DISEASE NEUROLOGY ALS HUNTINGTON'S • Selectively repress expression of a mutant allele while allowing for the expression of the healthy allele 13 • Blocking Nav1.7 in the DRG is expected to prevent the transmission of nociceptive pain signals to the brain • Progressive, with no disease modifying therapy Fabry Disease (isaralgagene civaparvovec or ST-920) | --- | --- | --- | --- | |-------|-------|-------|------------------------------------ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________ FORM 10-Q ________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-30171 ________________________ ...

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2023 Earnings Conference Call April 27, 2023 8:30 AM ET Company Participants Louise Wilkie - VP, IR and Corporate Communications Alexander D. Macrae - President and CEO D. Mark McClung - EVP and COO Prathyusha Duraibabu - SVP, Principal Accounting Officer and CFO Jason D. Fontenot - SVP and Chief Scientific Officer Nathalie Dubois-Stringfellow - SVP and Chief Development Officer Bettina M. Cockroft - CMO Conference Call Participants Benjamin Burnett - Stifel Grego ...

Forward-Looking Statements Pioneering and Delivering the Future of Genomic Medicines This presentation contains forward-looking statements regarding our current expectations. These forward-looking statements include, without limitation, statements relating to our focus on key strategic priorities, the potential to develop, obtain regulatory approvals for and commercialize durable, safe and effective therapies to treat certain diseases and the timing, availability and costs of such therapies, the potential t ...

Pioneering and Delivering the Future of Genomic Medicines Forward-Looking Statements 2 Four Clinical-Stage Programs Advancing Towards Potential Commercialization In-House Manufacturing Provides Flexibility and Control Sangamo in 2023: Value Thesis 1 2 Pioneer in CAR-Tregs • TX200 renal transplant Ph1/2 study progresses, with possible acceleration to prove biology and platform value. Second wave of potentially transformative autoimmune and neurology programs advancing into the clinic • Second of four wholly- ...

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q4 2022 Results Conference Call February 22, 2023 4:30 PM ET Company Participants Louise Wilkie - VP of IR and Corporate Communications Sandy Macrae - Chief Executive Officer Mark McClung - Chief Operating Officer Prathyusha Duraibabu - Chief Financial Officer Jason Fontenot - Chief Scientific Officer Nathalie Dubois-Stringfellow - Chief Development Officer Bettina Cockroft - Chief Medical Officer Andy Ramelmeier - Head of Technical Operations Conference Call Partici ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________________________________________________ Form 10-K _______________________________________________________________________________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the trans ...

Pioneering the Future of Genomic Medicines November 2022 Forward-Looking Statements This presentation contains forward-looking statements regarding our current expectations. These forward-looking statements include, without limitation, statements relating to the potential to develop, obtain regulatory approvals for and commercialize durable, safe and effective therapies to treat certain diseases and the timing, availability and costs of such therapies, the potential to use ZFP, ZFP-TF, CAR-Treg and other te ...

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Louise Wilkie - Investor Relations Sandy Macrae - Chief Executive Officer Nathalie Dubois-Stringfellow - Chief Development Officer Jason Fontenot - Chief Scientific Officer Prathyusha Duraibabu - Chief Financial Officer Bettina Cockroft - Chief Medical Officer Mark McClung - Chief Operating Officer Conference Call Participants Gena Wang - Barclays Yanan Zhu - Wells Fargo Ritu Baral - Co ...

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Louise Wilkie - Investor Relations Sandy Macrae - Chief Executive Officer Rob Schott - Head of Development Jason Fontenot - Chief Scientific Officer Prathyusha Duraibabu - Chief Financial Officer Bettina Cockroft - Chief Medical Officer Mark McClung - Chief Operating Officer Conference Call Participants Gregory Harrison - Bank of America Yanan Zhu - Wells Fargo Harshita Polishetty - Barcl ...